| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. | Chief Financial Officer | Common Stock | 12.9K | $83.7K | $6.49 | Jun 4, 2021 | Direct |
| Grace Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 10K | May 9, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| GRCE | Grace Therapeutics, Inc. | May 9, 2025 | 1 | $0 | 4 | May 13, 2025 | Director |
| ACST | Acasti Pharma Inc. | Dec 19, 2023 | 1 | $0 | 4 | Dec 20, 2023 | Director |
| ACST | Acasti Pharma Inc. | Oct 10, 2023 | 0 | $0 | 3 | Oct 20, 2023 | Director |
| VRCA | Verrica Pharmaceuticals Inc. | Jun 4, 2021 | 1 | $49.5K | 4 | Jun 7, 2021 | Chief Financial Officer |